SCHEMBL1355310

SCHEMBL1355310

CCOC(=O)c1ccc(C(=O)c2cnc3ccc(C#N)cn23)c(F)c1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.41
GLA P06280 2/20 0.41
GAA P10253 2/20 0.41
ELANE P08246 3/20 0.41
ADORA2A P29274 3/20 0.40
TGFBR1 P36897 3/20 0.40
KIT P10721 1/20 0.38
CSF1R P07333 1/20 0.38
PIK3CD O00329 1/20 0.37
PIK3R1 P27986 1/20 0.37
PIK3CA P42336 1/20 0.37
PIK3CB P42338 1/20 0.37
PIK3CG P48736 1/20 0.37
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
MAPK14 Q16539 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1355427 0.88 ADORA2A (0.51) KDM4EGLAGAAADORA2ATGFBR1
SCHEMBL1353059 0.86 ADORA2A (0.46) KDM4EGLAGAAADORA2ATGFBR1
SCHEMBL1355594 0.85 ADORA2A (0.44) KDM4EADORA2ATGFBR1KITCSF1R
SCHEMBL1355437 0.83 MAPK1 (0.43) KDM4EELANETP53MAPTALDH1A1
SCHEMBL2048928 0.82 TGFBR1 (0.51) KDM4EGLAGAAELANETGFBR1
SCHEMBL1355509 0.79 ADORA2A (0.65) ADORA2A
SCHEMBL15285968 0.75 MKNK1 (0.51) KDM4EGLAGAAELANETGFBR1
SCHEMBL14756580 0.73 CSF1R (0.41) KDM4EGLAGAAELANEADORA2A
SCHEMBL1354691 0.72 ADORA2A (0.64) KDM4EGLAGAAELANEADORA2A
SCHEMBL1354738 0.71 ADORA2A (0.57) KDM4EADORA2ATGFBR1KITALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9029393-B2 Adenosine receptor ligands and uses thereof KALDI PHARMA, SAS (FR) 2015-05-12 US disclosed
EP-2391625-B1 New adenosine receptor ligands and uses thereof DOMAIN THERAPEUTICS (FR) 2013-05-01 EP disclosed
EP-2391625-A1 NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF Domain Therapeutics (FR) 2011-12-07 EP disclosed
US-20110288074-A1 NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF DOMAIN THERAPEUTICS (FR) 2011-11-24 US disclosed
WO-2010084425-A1 NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF DOMAIN THERAPEUTICS (FR) 2010-07-29 WO disclosed
EP-2210891-A1 New adenosine receptor ligands and uses thereof Domain Therapeutics (FR) 2010-07-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288074-A1 NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF ADORA2A, ADORA1, ADORA2B KDM4E 4203/4885GLA 1681/4885GAA 487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.